NOVARTIS has announced that its generic division Sandoz is now free to market its tumour necrosis factor (TNF) inhibitor medicine adalimumab branded Hyrimoz, biosimilar-referenced to AbbVie's Humira.
The company said that it now has global resolution of all intellectual property related litigation with AbbVie with an agreement that sees Sandoz paying AbbVie royalties.
The above article was sent to subscribers in Pharmacy Daily's issue from 15 Oct 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 15 Oct 18
